Cargando…

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study

Melanoma survival increased with targeted- and immunotherapy agents, yet most patients ultimately progress and require salvage therapy. In our experience, some progressive disease patients on immune-checkpoint inhibitors (ICIs) demonstrate deep and sustained responses to chemotherapy. We hypothesize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadash-Bengad, Reut, Hajaj, Emma, Klein, Shiri, Merims, Sharon, Frank, Stephen, Eisenberg, Galit, Yakobson, Alexander, Orevi, Marina, Caplan, Nadia, Peretz, Tamar, Lotem, Michal, Cohen, Jonatan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033746/ https://www.ncbi.nlm.nih.gov/pubmed/32117727 http://dx.doi.org/10.3389/fonc.2020.00070

Ejemplares similares

SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
por: Hajaj, Emma, et al.
Publicado: (2020)

Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
por: Hirshoren, Nir, et al.
Publicado: (2020)

Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer
por: Uzana, Ronny, et al.
Publicado: (2015)

COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma
por: Avner, Mordechai, et al.
Publicado: (2021)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma
por: Shreberk‐Hassidim, Rony, et al.
Publicado: (2022)

Giant congenital melanocytic naevus with a novel CUX1–BRAF fusion mutation treated with trametinib
por: Molho‐Pessach, Vered, et al.
Publicado: (2022)

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
por: Sivan, Sapoznik, et al.
Publicado: (2012)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
por: Klein, M., et al.
Publicado: (2013)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2022)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

A nano-enhanced vaccine for metastatic melanoma immunotherapy
por: Salotto, Katelyn E., et al.
Publicado: (2022)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
por: Tsur, Neta, et al.
Publicado: (2019)

Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma
por: Kamminga, Nadia C.W., et al.
Publicado: (2022)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy
por: Fadel, Celine A, et al.
Publicado: (2022)

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report
por: Kuint, R., et al.
Publicado: (2017)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
por: Keller, Hilary R., et al.
Publicado: (2017)

Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy
por: Schwager, Zachary, et al.
Publicado: (2018)

Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma
por: Aria, Alexander B., et al.
Publicado: (2017)

Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy
por: Haraszti, Samantha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_54q33m6861lkcae7j301keqbbg